RT Book, Section
A1 Bourdet, Sharya V.
A1 Williams, Dennis M.
A2 DiPiro, Joseph T.
A2 Talbert, Robert L.
A2 Yee, Gary C.
A2 Matzke, Gary R.
A2 Wells, Barbara G.
A2 Posey, L. Michael
SR Print(0)
ID 1164511201
T1 Chronic Obstructive Pulmonary Disease
T2 Pharmacotherapy: A Pathophysiologic Approach, 10e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259587481
LK accesspharmacy.mhmedical.com/content.aspx?aid=1164511201
RD 2024/04/25
AB Content  UpdateJuly  30,  2019Using  C-Reactive  Protein  (CRP)  Testing  to  Guide  Antibiotic  Use  for  COPD  Exacerbations:  Almost  half  of  COPD  patients  experience  one  or  more  acute  exacerbations  of  symptoms  each  year.  Acute  exacerbations  are  triggered  by  a  variety  of  causes,  including  upper  respiratory  tract  infections  in  70%  to  80%  of  cases.  Most  patients  who  present  with  acute  worsening  of  COPD  symptoms  are  treated  with  antibiotics,  but  antibiotic  overuse  contributes  to  antimicrobial  resistance  and  increases  the  risk  of  adverse  effects.  Researchers  in  the  United  Kingdom  used  C-reactive  protein  (CRP)  testing  as  a  biomarker  to  assess  acute  COPD  exacerbations  and  to  guide  antibiotic  prescribing.  The  results  suggest  that  using  the  results  of  point-of-care  CRP  tests  could  significantly  reduce  the  number  of  antibiotics  prescribed  without  adversely  impacting  COPD  symptoms  or  hospitalization  rates.